News Release

Innovotech receives funding to advance environmentally friendly agricultural crop protection product

Business Announcement

Innovotech Inc.

Edmonton, Alberta, June 30, 2010 – Innovotech Inc. (TSX-V: IOT), a pioneer in the field of biofilm product development, has secured funding in excess of $900,000 from Agriculture and Agri-Food Canada to facilitate the commercialization of Agress™, its unique, environmentally friendly seed treatment and plant spray designed to protect crops against both bacterial and fungal infections.

"With the potential to increase crop yields and improve product quality while minimizing the risk of antibacterial resistance, Agress™ has the opportunity to provide a cost-effective solution for the Agricultural Industry where current technologies either have undesirable effects on the environment or do not work well," said Ken Boutilier, President and CEO of Innovotech Inc.

The two year, repayable funding, administered in Alberta through the Agriculture and Food Council, will focus on field trials to expand the potential applications of Agress™ from pulse crops (dry beans, dry peas, lentils, chickpeas) and soybeans to high value horticultural crops such as tomatoes, peppers, and potatoes. The funding will also be used to support regulatory approval submissions for Agress™.

###

About Innovotech Inc.:

Innovotech Inc. is a pioneer in the field of biofilm product development, focused on providing innovative and practical solutions to medical, agricultural and industrial problems caused by microbial biofilms. Biofilms are responsible for a host of diseases both in agriculture and human health due to their inherent resistance to existing antibiotics and disinfectants. There are currently no antibiotics, disinfectants, diagnostics or regulatory standards designed specifically for biofilm-forming organisms.

Innovotech currently has two products in advanced stages of development: Agress™ a unique, environmentally friendly seed treatment and plant spray designed to protect crops against both bacterial and fungal infections, and bioFILM PA™, the first diagnostic kit to assist physicians in the selection of the most effective combination antibiotic treatment of patients with biofilm-based chronic lung infections.

For more information contact:

Ken Boutilier, President and CEO
Innovotech Inc.
Phone: (780) 448-0585 ext. 221
Fax: (780) 424-0941
Email: ken.boutilier@innovotech.ca
Website: www.innovotech.ca

This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company's reliance on a small number of customers including government organizations; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; the Company's exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should management's assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward-looking statements, except as required by applicable law.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.